Mechanism studies have shown that HBx conferred resistance to the S-phase arrest-inducing chemotherapeutics by specifically inhibiting the phosphorylation of checkpoint kinase 2 (CHK2, a key DNA damage response protein) in DLBCL cells (23). The gene discussed is CHEK2; the disease is diffuse large B-cell lymphoma.